Cargando…

Phase II evaluation of mitozolomide in ovarian cancer.

Detalles Bibliográficos
Autores principales:	Harding, M., Northcott, D., Smyth, J., Stuart, N. S., Green, J. A., Newlands, E.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1988
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246691/ https://www.ncbi.nlm.nih.gov/pubmed/3348943

Ejemplares similares

Plasma and tissue disposition of mitozolomide in mice.
por: Brindley, C. J., et al.
Publicado: (1986)

Mitozolomide activity on human cancer cells in vitro.
por: Erba, E., et al.
Publicado: (1986)

Antitumour imidazotetrazines, Part IX. The pharmacokinetics of mitozolomide in mice.
por: Goddard, C., et al.
Publicado: (1985)

Mitozolomide-induced sensitisation of mammalian cells in vitro to radiation.
por: McKeage, M. J., et al.
Publicado: (1989)

The logistics of broader pre-clinical evaluation of potential anti-cancer agents with reference to anti-tumour activity and toxicity of mitozolomide.
por: Bibby, M. C., et al.
Publicado: (1988)

Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease.
por: Gundersen, S., et al.
Publicado: (1987)

The effects of pretreatment of human tumour cells with MNNG on the DNA crosslinking and cytotoxicity of mitozolomide.
por: Gibson, N. W., et al.
Publicado: (1985)

A negative phase II trial methylene dimethane sulphonate in advanced ovarian cancer (Cancer Research Campaign Phase I/II Trials Committee).
por: Smith, D. B., et al.
Publicado: (1988)

Phase I-II study of carboplatin vincristine methotrexate and bleomycin (COMB) in carcinoma of the cervix.
por: Rustin, G. J., et al.
Publicado: (1988)

Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer. CRC Phase II Clinical Trials Committee.
por: Kaye, S. B., et al.
Publicado: (1992)

Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.
por: Kerr, D. J., et al.
Publicado: (1989)

Phase II trial of trimelamol in refractory ovarian cancer.
por: Judson, I. R., et al.
Publicado: (1991)

Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
por: Kerr, D. J., et al.
Publicado: (1995)

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer
por: Hasan, J, et al.
Publicado: (2005)

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.
por: Gietema, J. A., et al.
Publicado: (1995)

Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer
por: D'Agostino, G, et al.
Publicado: (2003)

A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer
por: Vasey, P A, et al.
Publicado: (2003)

Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.
por: Woll, P. J., et al.
Publicado: (1995)

A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
por: Lind, M. J., et al.
Publicado: (1992)

Phase II biomarker trial of a multimarker diagnostic for ovarian cancer
por: Edgell, Tracey, et al.
Publicado: (2010)

Phase I trial of elactocin.
por: Newlands, E. S., et al.
Publicado: (1996)

Early evaluation of tumour metabolic response using [(18)F]fluorodeoxyglucose and positron emission tomography:a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas
por: Brock, C S, et al.
Publicado: (2000)

Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study
por: Rosenthal, Adam N., et al.
Publicado: (2017)

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer
por: Guppy, A E, et al.
Publicado: (2004)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer
por: Penson, Richard T, et al.
Publicado: (2023)

Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
por: Ray-Coquard, I, et al.
Publicado: (2009)

A prognostic model for ovarian cancer
por: Clark, T G, et al.
Publicado: (2001)

Phase 1 study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas
por: Newlands, E S, et al.
Publicado: (2003)

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.
por: Blackledge, G., et al.
Publicado: (1989)

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
por: Lorusso, D, et al.
Publicado: (2012)

Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life.
por: Twelves, C. J., et al.
Publicado: (1994)

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
por: Poveda, A., et al.
Publicado: (2017)

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
por: Newlands, E. S., et al.
Publicado: (1992)

Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients
por: Corrie, P, et al.
Publicado: (2002)

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
por: Krasner, C N, et al.
Publicado: (2007)

Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
por: Colon-Otero, Gerardo, et al.
Publicado: (2020)

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
por: Reardon, D A, et al.
Publicado: (2009)

Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.
por: Seymour, M. T., et al.
Publicado: (1994)

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
por: Pecorelli, S., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_s03tvqt5rvpggco9jf5q5nbrre